Enlivex Therapeutics Ltd. has announced that it will hold an Extraordinary General Meeting of Shareholders on February 3, 2026, at its offices in Ness Ziona, Israel. During the meeting, shareholders will vote on several key proposals, including approving amendments to the Company’s Articles of Association. These amendments involve changing the Company’s name to “Enlivex Ltd.” or another name containing “Enlivex” as approved by management, classifying the Board of Directors into three classes with staggered three-year terms, and increasing the Company’s authorized share capital. Additional resolutions include approving amendments to the exemption and indemnification agreement for directors and the Chief Executive Officer, as well as the approval of an equity bonus in the form of restricted share units for the Chief Executive Officer.